	US 12,138,343 B2
	Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2
Julio César Vega, Buenos Aires (AR)
Assigned to Amcyte Pharma Inc., Boston, MA (US)
Filed by Amcyte Pharma Inc., Boston, MA (US)
Filed on May 17, 2021, as Appl. No. 17/321,729.
Application 17/321,729 is a continuation of application No. 16/900,488, filed on Jun. 12, 2020, granted, now 11,013,687.
Claims priority of provisional application 63/035,982, filed on Jun. 8, 2020.
Prior Publication US 2021/0386667 A1, Dec. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/047 (2006.01); A61K 31/731 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01)

CPC A61K 9/0078 (2013.01) [A61K 9/0043 (2013.01); A61K 9/08 (2013.01); A61K 31/047 (2013.01); A61K 31/731 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01)]

2 Claims

1. A composition for nebulizing upper and/or lower airways consisting of a solution having about 0.001% w/v to about 0.50% w/v iota carrageenan and about 0.3% w/v to about 0.9% w/v of sodium chloride as osmolyte to treat infections caused by SARS-COV-2 and other related coronaviruses.